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Abstract: One of the best examples of the renaissance of Src as an open door to cancer has 
been the demonstration that just five min of Src activation is sufficient for transformation 
and also for induction and maintenance of cancer stem cells [1]. Many tyrosine kinase 
receptors, through the binding of their ligands, become the keys that unlock the structure of 
Src and activate its oncogenic transduction pathways. Furthermore, intracellular isoforms 
of these receptors, devoid of any tyrosine kinase activity, still retain the ability to unlock 
Src. This has been shown with a truncated isoform of KIT (tr-KIT) and a truncated isoform 
of VEGFR-1 (i21-VEGFR-1), which are intracellular and require no ligand binding, but are 
nonetheless able to activate Src and induce cell migration and invasion of cancer cells. 
Expression of the i21-VEGFR-1 is upregulated by the Notch signaling pathway and 
repressed by miR-200c and retinoic acid in breast cancer cells. Both Notch inhibitors and 
retinoic acid have been proposed as potential therapies for invasive breast cancer. 
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1. The VEGF Receptor Tyrosine Kinase Family 
Three structurally related tyrosine kinase receptors of the vascular endothelial growth factor 
(VEGF) have been characterized in mammals: VEGFR-1, VEGFR-2 and VEGFR-3 [2]. These 
receptors consist of a seven immunoglobulin-loop extracellular domain, a transmembrane domain, a 
juxtamembrane domain, a split tyrosine kinase domain and a C-terminal tail that mediates the 
interaction of VEGFR with downstream proteins in the signaling pathway. Binding of VEGF at the  
N-terminal part of the extracellular domain results in the formation of receptor homo- or heterodimers, 
a step required for its activation. Dimerization of the receptor induces a conformational change of the 
intracellular kinase domain that exposes the ATP binding site. Following ATP binding, auto or 
transphosphorylation in the receptor dimer leads to the activation of downstream signal transducer 
proteins. The activity of the receptors is regulated by internalization and degradation or by 
dephosphorylation by protein tyrosine phosphatases. 
VEGFR-1 (also known as Flt-1) is a 180–185 kDa glycoprotein [3–5] that is activated by VEGF 
(Figure 1). Three ligands—VEGF-A, VEGF-B and PlGF (Placental Growth Factor)—bind to the 
immunoglobulin loop 2 of the extracellular domain of VEGFR-1, requiring loops 1 and 3 only to 
increase binding affinity. The binding affinity of VEGFR-1 is higher by one order of magnitude 
compared to VEGFR-2, while its tyrosine kinase activity is one order of magnitude lower [6–8]. The 
ligands bind to the receptors in a specific fashion. VEGF-B and PlGF bind selectively to VEGFR-1, 
whereas VEGF-A binds to VEGFR-1 and VEGFR-2. Binding of VEGF-A induces the formation of 
receptor heterodimers in VEGFR-1 and VEGFR-2 co-expressing cells [9], in contrast to PlGF or 
VEGF-B, which are unable to attach to VEGFR-2 [10]. However, binding of PIGF to VEGFR-1 
results in the phosphorylation of VEGFR-2 and may sensitize the receptor to subsequent activation by 
VEGF-A [11]. 
Figure 1. Schematic structure of VEGFR-1 and KIT isoforms. At the center, VEGFR-1 
and KIT-homodimer full-length transmembrane receptors. Laterally, extracellular and 
intracellular truncated isoforms. The intracellular truncated isoforms are the result of 
alternative transcription initiation in intronic sequences of VEGFR-1 and KIT genes. 
sVEGFR-1, soluble VEGFR-1; PlGF, Placental Growth Factor; sKIT, soluble KIT. 
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Overexpression of VEGFR-1 in insect cells or mammalian cells has allowed the identification of 
several VEGFR-1 tyrosine phosphorylation sites, namely Tyr794, Tyr1169, Tyr 1213, Tyr1242, Tyr1327 and 
Tyr1333 [5,12,13]. The phosphorylation pattern of VEGFR-1 depends on the ligand. For instance, PlGF, 
but not VEGFA, induces phosphorylation of Tyr1309 [11]. These phosphorylations determine the ability 
of the receptor to activate different components in the signal transduction. Tyr794 [12] and Tyr1169 [14] 
are involved in binding and activation of phospholipase C-γ, whereas Tyr1213 binds to SH2-containing 
proteins [13,15]. VEGFR-1 transduces signals for migration and invasion of cancer cells, via the 
cytoplasmic tyrosine kinase Src [16,17]. 
2. Truncated Isoforms of VEGFR-1 
The VEGFR-1 gene in humans consists of 30 exons spanning more than 193 Kb [10]. One 
truncated extracellular soluble isoform (sVEGFR-1/sFlt1) is produced using the first 13 exons and an 
additional sequence located in intron 13 [18]. The sVEGFR1 consists of six immunoglobulin-loops as 
illustrated in Figure 1. We characterized another transcript that contains the first 14 exons and an 
additional sequence of intron 14 (s14VEGFR-1), which encodes a protein with a C-terminal polyserine 
tail (GenBank EU360600). This isoform was reported by Thomas et al. [19,20]. Soluble VEGFR-1 can 
also be obtained by post-translational processing. A truncated extracellular isoform derives from the 
endoproteolytic cleavage of VEGFR-1 in endothelial cells [21]. Ectodomain shedding of VEGFR-1 
has also been observed in leukemic cancer cells [22]. Following the removal of the ectodomain, the 
remnant of VEGFR-1 remains attached to the membrane and the activity of γ-secretase is required for 
its release to the cytosol. The soluble forms of VEGFR-1 can modulate the VEGF/VEGFR 
transduction pathways. 
We have characterized several transcripts that initiate transcription in intronic sequences of the 
VEGFR-1 gene [23]. These transcripts have lost the sequences coding for the extracellular domains of 
the receptor and contain either the full set of intracellular domains or a partial kinase domain followed 
by the C-terminal sequence (Figure 2). Five transcripts have been identified and named after the intron 
where transcription initiates (i15VEGFR-1, i18VEGFR-1, i19VEGFR-1, i21VEGFR-1 and i28VEGFR-1). 
Additionally, two isoforms (i15asVEGFR-1 and i21asVEGFR-1) result from alternative splicing of 
i15VEGFR-1 and i21VEGFR-1, respectively. All transcripts incorporate additional 5' leader sequences 
derived from the corresponding 5' intron [23] (GenBank JF509744 and JF509745). 
Transcript i21VEGFR-1 is expressed in human endothelial cells, macrophages, fibroblasts, breast 
cancer MDA-MB-231 cells, and human placenta [23]. The i21VEGFR-1 protein is expressed in human 
endothelial cells and MDA-MB-breast cancer cells [23,24]. The human isoforms i19VEGFR-1 and 
i28VEGFR-1 are expressed in human testis (GenBank JF509744 and JF509745). The two i21VEGFR-1 
transcripts initiate at nucleotide 157 of intron 21. Isoform i21asVEGFR-1 putative coding region would 
start with the specific amino acid MNSDLLV sequence, followed by the whole CDS of exon 22. 
Putative protein i21asVEGFR-1 would have 360 amino acids, and the sequence would be identical to 
the amino acids 986–1338 (AF063657) of the full-length VEGFR-1 (Figure 2). The protein 
i21VEGFR-1 would contain 343 amino acids, and the sequence would be identical to the amino acids 
996–1338 (AF063657) of the full-length VEGFR-1 (Figure 2). These isoforms conserve 163 
(i21VEGFR-1) and 174 (i21asVEGFR-1) of the 332 amino acids of the kinase domain, including none 
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(i21VEGFR-1) or 11 amino acids (i21asVEGFR-1) of the kinase insert. Both i21VEGFR-1 isoforms lack 
the ATP-binding domain [23].  
Protein i21VEGFR-1 was detected by Western blot analysis [23,24]. To confirm the specificity of 
the bands detected by the anti-VEGFR-1 antibody, we inhibited the expression of VEGFR-1 and 
i21VEGFR-1 by RNA interference. Bands of 170 kD and 39 Kd, corresponding to the full-length 
transmembrane VEGFR-1 and the truncated intracellular isoform, respectively, disappear after RNA 
interference in human endothelial cells (HUVECs). Furthermore, the band of 39 kD, corresponding to 
i21Flt1, is no longer detectable after RNA interference of i21VEGFR-1 in MDA-MB-231 breast cancer 
cells [24]. 
Figure 2. Schematic structure of the intracellular truncated isoforms of VEGFR-1. Amino 
acid numbers correspond to the full length transmembrane receptor. JM, juxtamembrane 
domain; TK1, kinase domain, ATP binding; KI, Kinase insert; TK2, kinase domain, 
phosphotransferase; CT, C-terminal tail region. 
 
3. The KIT Receptor Tyrosine Kinase Family 
The KIT receptor belongs to the type III group of receptor protein tyrosine kinases, together with 
the vascular endothelial growth factor receptor (VEGFR), the receptor for platelet-derived growth 
factor (PDGFR) and the receptor for the granulocyte macrophage colony-stimulating factor-1 
(CSGFR) [25–28]. The KIT full-length transmembrane receptor consists of an extracellular domain 
composed of five immunoglobulin-like repeats, a transmembrane domain, a juxtamembrane domain, a 
tyrosine domain divided into two parts by a kinase insert domain, and a C-terminal tail (Figure 1). Binding 
of the ligand stem factor to the KIT receptor results in dimerization of two receptor monomers, followed by 
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autophosphorylation of specific tyrosine residues and recruitment of signaling proteins to the homodimer. 
Phosphorylation of the signaling proteins activates several transduction pathways.  
The KIT gene codes for two full-length receptors that result from alternative splicing: KITA and 
KITB. They differ by the presence (KITA) or the absence (KITB) of the amino acid sequence GNNK 
in the juxtamembrane region of the extracellular domain. Activation of KITB in a myeloid cell line 
produces activation of Src rather than the PI3 kinase pathway. KITB, but not KITA, shows constitutive 
tyrosine phosphorylation when transfected into COS7 cells [29] and it is tumorigenic in nude mice 
when transfected to NIH3T3 fibroblasts [30]. 
4. Truncated KIT Isoforms 
In addition to the full-length transmembrane KIT receptors, there is a truncated extracellular form 
of KIT (sKIT) consisting almost entirely of the extracellular domains of the full receptor. The soluble 
form is produced by post-translational proteolytic cleavage of full-length KIT. The proteolytic cleavage 
generates a truncated intracellular form of 50 kDa that remains attached to the cell membrane [31–33]. 
Both KIT isoforms A and B are susceptible to cleavage. The soluble form can modulate the stem 
factor/KIT transduction pathway. 
The third protein encoded by the KIT gene arises from transcription initiation at KIT intron 15 in 
humans and intron 16 in rodents [34]. Transcription probably occurs through the use of an alternative 
cryptic promoter. The truncated intracellular isoform is expressed in postmeiotic male germ cells, 
hematopoietic stem cells, progenitor cells [35], tumor cell lines and tumors [36]. The truncated 
intracellular KIT protein is 202 amino acids long and lacks the extracellular domains, transmembrane 
domain, juxtamembrane domain, ATP binding domain and most of the kinase insert domain of the 
full-length receptor. It contains just a short sequence of the interkinase segment, the 
phosphotransferase domain and the C-terminal tail of the receptor. While other truncated tyrosine 
kinase receptors aberrantly expressed in cancer are constitutively active kinases, truncated c-KIT does 
not contain the ATP binding domain and should be catalytically inactive. However, despite being 
devoid of tyrosine kinase activity, truncated KIT is able to activate the Src kinase pathway [37]. 
5. Src Activation through Receptor Tyrosine Kinases and Their Intracellular C-Terminal 
Truncated Isoforms 
The c-SRC non-receptor tyrosine kinase is overexpressed and activated in a large number of human 
malignancies and has been linked to the development of cancer and progression to distant  
metastases [38–40]. Src (for sarcoma) was the first oncogene discovered, and its protein product was 
the first identified tyrosine kinase [41]. In 1909, Peyton Rous, a young pathologist working at the 
Rockefeller Institute in New York, discovered that cell-free filtrates obtained from a spontaneous 
chicken sarcoma could transmit the disease to other individuals, postulating the hypothesis of viral 
transmission [42,43]. The relevance of Rous’s discovery was recognized 55 years later, as he received 
the Nobel Prize of Physiology or Medicine. The viral oncogene (v-Src) was a mutated version of the 
chicken Src normal gene, which was incorporated into the viral genome by recombination and encoded 
a protein tyrosine kinase [41]. The discovery of the cellular origin of a viral oncogene suggested that 
normal genes could become oncogenic if inappropriately activated.  
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In addition to Src, other members of the family of non-receptor-tyrosine kinases have been 
characterized: Fyn, Yes, Lyn, Lck, Hck, Blk, Yrk and Fgr [38]. The Src protein is composed of seven 
domains [38,44,45] (Figure 3): (1) An N-terminal region, which contains a myristoylation sequence, 
which is essential for binding to the inner surface of the cell membrane. (2) A unique domain that 
confers specificity to the different members of the Src family. (3) The SH3 domain, which binds to 
proline sequences and mediates intra and inter-molecular interactions. (4) The SH2 domain, which 
binds phosphorylated tyrosine residues of the Src molecule itself or other proteins. (5) A linker 
domain, involved in the intramolecular binding with SH3. (6) A catalytic domain that contains an 
autophosphorylation site at Tyr419, required for maximal kinase activity, and (7) A C-terminal tail, 
containing the negative-regulatory Tyr530. 
Figure 3. Schematic representation of Src in the low activity state (left) and the active state 
(right). In the low activity configuration, the SH2 domain binds the phosphorylated C-terminal 
Tyr530, while the SH3 domain interacts with the linker domain, promoting a relative 
“closed” conformation. In the active configuration, SH2 and SH3 domains are released 
from the intramolecular interactions with autophosphorylation of Tyr419, which enhances 
the catalytic activity of Src. Activation of Src is mediated by activation of transmembrane 
tyrosine receptors (RTK) upon binding the corresponding ligands or, alternatively, by the 
C-terminal intracellular truncated isoforms. 
 
When Tyr530 is phosphorylated, the C-terminal domain binds to the SH2 domain, and Src acquires a 
closed conformation with low activity. Binding of SH3 to the proline rich linker domain stabilizes this 
low activity conformation [46,47]. These intramolecular interactions keep the active site of the kinase 
poorly accessible to substrates [48]. Upon dephosphorylation of Tyr530 or displacement of the SH2 and 
SH3 intramolecular interactions by other proteins, Src-like kinases acquire a relaxed conformation. This 
allows autophosphorylation of Tyr419 in the catalytic site and the achievement of maximal kinase  
activity [47]. Since the viral oncogenic protein v-Src lacks the regulatory C-terminal tyrosine residue, it 
is constitutively active and oncogenic. 
The tyrosine kinase c-Src interacts physically with multiple tyrosine kinase receptors via its SH2 
domain. Src is a substrate of RTKs and, at the same time, an activator of RTKs. This bidirectional 
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activation creates a positive-regulatory loop that contributes to the robustness and persistence of RTK 
signaling [49]. The binding of RTK with its corresponding ligand leads to receptor dimerization and 
autophosphorylation on tyrosine residues of the C-terminal tail. Phosphorylated tyrosine residues 
recruit and activate Src, which then phosphorylates RTK and augments RTK tyrosine kinase activity. 
The RTK cooperating receptors include epidermal growth factor (EGFR), vascular endothelial growth 
factor (VEGFR), platelet derived growth factor receptor (PDGFR), fibroblast growth factor receptor 
(FGFR), insulin-like growth factor receptor (IGFR-1), hepatocyte growth factor receptor (MET), 
colony stimulating growth factor receptor (CSGFR) and stem factor receptor (KIT), among others. All 
these receptors and the corresponding ligands are the keys that can unlock the closed structure of Src, 
opening the door to cancer. In addition, it is also possible to unlock Src without keys, by using the 
truncated C-terminal isoforms of KIT and VEGFR-1, which lack the ATP binding domain and 
therefore present no tyrosine kinase activity. Truncated KIT and Src kinase Fyn interact physically 
through Tyr161 of truncated KIT [37]. Upon binding to tr-KIT, Fyn phosphorylates Tyr161 of tr-KIT in 
vitro and in transfected cells. A hypothetical model assumes that Fyn, in the low activity conformation, 
phosphorylates tr-KIT. This phosphorylation allows the interaction of the phosphorylated tr-KIT with 
the SH2 domain of Fyn, displacing the intramolecular inhibition [37]. Upon relaxation, Fyn 
autophosphorylates and phosphorylates the proteins involved in the transduction pathway. 
The introduction of v-Src into normal cells produces a fully transformed phenotype with 
simultaneous activation of several transduction pathways such as STAT3, Ras/MAPK and PI3K/AKT. 
Activation of Src increases migration, invasion and metastasis. Src has a prominent role in invasive 
migration. Upon activation, Src disrupts adherens junctions between cells stabilized by E-cadherin. 
Phosphorylation by Src of the E-cadherin-β-catenin complex results in dissociation of β-catenin and 
functional loss of E-cadherin [50]. Free β-catenin translocates to the nucleus and induces transcription 
of genes related with the epithelial-mesenchymal transition (EMT). Src activation is a potent trigger 
for EMT, which is reverted back by inhibition of Src. Activated Src also disrupts focal adhesions that 
attach cells to the extracellular matrix through integrins. In addition, activated Src promotes the 
expression of matrix-degrading proteases such as metalloproteinases that enhance the metastatic 
potential [51] (Figure 4). Src activation also increases angiogenesis, facilitating metastasis formation. 
Src induces angiogenesis in two different ways: (1) Inducing the expression of angiogenic factors such 
as VEGF and IL8 [52–54] and (2) Cooperating with VEGF receptors [16]. Inhibition of Src can 
suppress endothelial cell proliferation and migration of human umbilical vein endothelial cells [55]. 
Recently, Iliopoulos et al. [1] reported an interesting experimental model to follow the consequences of 
Src activation in cancer. A transient activation of Src, as short as 5 min, was sufficient to induce stable 
neoplastic transformation in immortalized breast epithelial cells. In this model, a spontaneously 
immortalized cell line, derived from normal mammary epithelial cells, was transfected with ER-Src, a 
fusion of the Src kinase oncoprotein (v-Src), and the ligand binding domain of the estrogen receptor. 
When these cells were treated with tamoxifen (TAM), a phenotypic transformation occurred. The 
transformed cells formed colonies in soft agar, showed increased motility and invasive ability, and tumor 
formation upon injection in nude mice. Transformed ER-Src cells formed mammospheres, whereas the 
untransformed cells did not. Strikingly, mammospheres derived from ER-Src-transformed cells could 
be passaged in vitro for 12 generations in the absence of TAM, with the number of mammospheres 
increasing upon passage. As expected from the absence of TAM, the passaged mammospheres did not 
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contain activated Src (assayed by phosphorylation of Y419), unlike the initially transformed cells in the 
presence of TAM. Remarkably, when TAM treatment lasted only 5 min, stable transformation was 
produced. A progressive increase of the time of TAM treatment reduced the time required to obtain the 
transformed phenotype.  
Figure 4. Src signaling pathways and function. Binding of ligands to the corresponding 
transmembrane tyrosine kinase receptors (RTK) or intracellular truncated C-terminal isoforms 
of RTKs can activate Src. Activation of Src is involved in different signaling pathways. 
Particularly important are the disruption of adherens junctions stabilized by E-cadherin and the 
disruption of focal adhesions, which promotes migration, invasion and metastasis. 
 
In this model, NF-κB is activated within 30 min after Src activation and remains highly active until 
36 h after TAM treatment. Activation of NF-κB rapidly increases the expression of the protein Lin28B 
and increased levels of Lin28B inhibit the expression of the microRNA let-7 through a 
posttranscriptional mechanism. Lin28B and its ability to rapidly inhibit let-7 microRNAs upon Src 
activation is a key early step that is important for cellular transformation. Let-7 microRNA directly 
inhibits expression of IL6 through binding the 3' UTR of the IL6 mRNA. IL6 is important for 
transformation. When IL6 was depleted by a monoclonal antibody, the morphological changes 
associated with transformed cells were blocked, and colony formation and cell motility were inhibited.  
IL6 acts primarily through its receptor to activate the JAK/STAT pathway, and inhibition of the IL6 
receptor reduces transformation and tumorigenicity. STAT3, a DNA-binding transcriptional activator 
that is phosphorylated in response to IL6, is an important mediator of cellular transformation. IL6 
inhibition strongly reduces STAT3 expression and phosphorylation, indicating that STAT3 activation 
is IL6 dependent. IL6 activates NF-κB and activation of NF-κB increases IL6 expression, resulting in a 
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positive feedback loop [1]. The positive feedback loop induced by Src activation, and the resulting 
transformed phenotype, are maintained in the absence of Src activity.  
The positive feedback loop that produces IL6 is important for cancer cells from diverse 
developmental lineages. Eight out of 15 different kinds of cancer cell lines show Lin28B 
overexpression, let-7 downregulation, and high levels of IL6. Perturbation of any component of the 
regulatory circuit significantly reduced the tumorigenicity and motility of lung (A549), hepatocellular 
(HepG2), breast (MDA-MB-231), prostate (PC3), and colon (Caco2) cancer cells. In all cases, these 
perturbations resulted in reduced expression of IL6, suggesting the importance of IL6 in maintaining 
the transformed phenotype.  
In addition to cell transformation, the expression of IL6, after Src activation, is important for 
induction and maintenance of cancer stem cells [56]. IL6 regulates, negatively, the micro RNA family 
miR-200 and, positively, the Notch-3 transduction pathway. Both downregulation of miR-200 and 
activation of Notch are important for induction and maintenance of cancer stem cells [57,58] (Figure 5). 
Figure 5. Signaling circuit driving transformation and tumorigenesis. After Src activation, 
NF-κB is activated and IL6 is produced [1]. STAT3, a DNA-binding transcriptional 
activator that is phosphorylated in response to IL6, is an important mediator of cellular 
transformation. IL6 activates NF-κB and activation of NF-κB increases IL6 expression, 
resulting in a positive feedback loop. In addition to cell transformation, the activation of 
IL6 expression is important for induction and maintenance of cancer stem cells. IL6 
regulates negatively the micro RNA family miR-200 and positively the Notch-3 
transduction pathway. Both, downregulation of miR-200 and activation of Notch are 
important for induction of the epithelial-mesenchymal transition and for induction and 
maintenance of cancer stem cells. 
 
6. Expression of the Full-Length VEGFR-1 and the Truncated Intracellular Isoforms in Cancer 
Cells is Related with Increased Migration and Invasion through Activation of Src 
Hiratsuka et al. [59] originally reported that mouse lacking the tyrosine domain of VEGFR-1 
(Flt1TK−/− mice) had impaired metastatic progression. Several reports demonstrated that inhibition of 
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VEGFR-1 by anti-VEGFR-1 peptide blocked micro- and macrometastasis, while overexpression of 
placental growth factor (PlGF), which signals exclusively through VEGFR-1, increased metastatic 
spread [60,61]. VEGFR-1 is required for lung adenocarcinoma cell invasion and metastasis [62]. 
Knocking down VEGFR-1 in lung cancer cells decreased proliferation in monolayer culture, colony 
formation in soft agar, invasion in coculture with cancer associated fibroblasts, and metastatic potential 
following subcutaneous injection into syngeneic mice [62]. Similarly, VEGFR-1 maintained cell 
survival in colorectal and pancreatic cancer cells, and was required for tumor cell migration and 
invasion [63,64]. VEGFR-1 activation induced tumor cell epithelial-mesenchymal transition and 
increased cell invasion through phosphorylation of Src family members [16,65,66]. 
In addition to expression of VEGFR-1 in cancer cells, expression of VEGFR-1 in cells of the tumor 
microenvironment is also important for metastasis. VEGFR1-positive hematopoietic bone marrow 
progenitors initiate the pre-metastatic niche [67]. Knockdown of VEGFR-1 in myelomonocytic cells 
eradicates micro- and macrometastases (see Kaplan et al. reply to [68]). Chemotherapy-induced expression 
of VEGFR-1 on endothelial cells can create an environment favorable to tumor cell homing [69]. 
The full-length VEGFR-1 receptor and the soluble form (sVEGFR-1) were not detected in  
MDA-MB-231 by Northern blot analysis of total RNA [23], in accordance with a previous report [70] 
and were barely detectable by RT-PCR in comparison with a high expression in endothelial cells. 
Highly invasive MDA-MB-231 breast cancer cells showed epigenetic gene silencing of VEGFR-1 as a 
consequence of promoter hypermethylation [71]. Aberrant promoter methylation of VEGFR-1 was 
also reported in prostatic cancer [72] and in 15 cancer cell lines studied [71]. Western blot analysis showed 
high expression of the full-length VEGFR-1 receptor in endothelial cells but not in MDA-MB-231 
cells [23]. Only one band of higher mobility than the corresponding to the full-length VEGFR-1 
transcript was detected by Northern blot in MDA-MB-231 cells. This band was identified as the 
intracellular truncated isoform i21VEGFR-1 [23]. 
The amount of i21VEGFR-1, transcript and protein, expressed in MDA-MB-231 cells, varies with 
cell culture conditions [23]. When MDA-MB-231 culture medium was changed every day, the amount 
of i21VEGFR-1 was barely detectable. However, the amount increased markedly when cells were 
maintained for 5–6 days without any change of the culture medium, suggesting that a paracrine control 
may increase expression of i21VEGFR-1 [23].  
Since i21VEGFR-1, transcript and protein is the main VEGFR-1 isoform expressed in MDA-MB-231 
breast cancer cells, our initial approach to study the function of this isoform consisted in inhibiting its 
expression by RNA interference or overexpressing the intracellular isoform by transfection of 
i21VEGFR-1 [23]. The ability of MDA-MB-231 siRNA transfected cells to migrate or to invade 
through Matrigel was substantially decreased after silencing i21VEGFR-1 and markedly increased after 
overexpression of i21VEGFR-1, as compared to control cells [23].  
To determine if Src is activated by the intracellular isoform i21VEGFR-1 we performed experiments 
of interference or overexpression of i21VEGFR-1 in MDA-MB-231 cells [23]. Silencing i21VEGFR-1 
by RNA interference decreases Src phosphorylation at Tyr419, as demonstrated by Western blot 
analysis with a specific antibody against Y419-Src peptide. To test further the effect of i21VEGFR-1 on 
Src phosphorylation at Tyr419, we transfected MDA-MB-231 cells with i21VEGFR-1. Cells stably or 
transiently transfected with i21VEGFR-1 upregulate the active form of Src. Src activation has been 
implicated in cell invasion and could be a potential mechanism to explain the increase of cell 
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invasiveness produced by i21VEGFR-1. Src kinase inhibition by PP2 produces a similar effect to 
silencing i21VEGFR-1, decreasing the capacity of MDA-MB-231 cells to pass through a Matrigel 
barrier [23]. 
7. Regulation of Expression of Truncated Intracellular VEGFR-1 in Breast Cancer Cells 
Expression of i21-VEGFR1, transcript and protein in MDA-MB-231 highly invasive breast cancer 
cells is controlled by the Notch signaling pathway [23,24]. Interference of the Notch signaling pathway by 
the inhibitor of γ-secretase DAPT decreases the expression of i21VEGFR-1 in MDA-MB-231cells [24]. 
Interference of the Notch-1 and Notch-3 signaling pathways by siRNA downregulates the truncated 
isoform in these cells [24]. By contrast, activation of Notch signaling in vitro by the ligand Dll4 
activates the expression of i21VEGFR-1 protein in MDA-MB-231 cells [24].  
A role for the Notch pathway in tumor metastasis has been proposed [73–77]. Since we have 
reported that i21VEGFR-1 can activate Src and increase the invasiveness of MDA-MB-231 cells [23], 
Notch-1 and Notch-3 signaling pathways could contribute to the invasive phenotype of MDA-MB-231 
breast cancer cells through upregulation of i21VEGFR-1 protein. 
In addition to the positive regulation by the Notch pathway, the expression of i21VEGFR-1 is 
negatively regulated by the micro RNA family miR-200 [24].VEGFR-1 has been validated as a  
miR-200s target and overexpression of miR-200s reduced significantly the expression of VEGFR-1 in 
both lung adenocarcinoma cells [62] and colon cancer cells [78]. Both the full-length receptor and the 
intracellular truncated i21VEGFR-1 transcript possess the same 3’UTR with the target sequences for 
miR-200s. The expression of the protein i21VEGFR-1 was markedly reduced in MDA-MB-231 cells 
transfected with pre-miR-200c [24]. When MDA-MB-231 cells were cultured during six days without 
changing the culture medium, miR-200c decreased markedly, while i21VEGFR-1 increased [24]. 
Reexpression of miR-200s in highly invasive MDA-MB-231 breast cancer cells decreased motility and 
invasion in vitro and suppressed pulmonary metastasis in vivo [79].  
Addition of retinoic acid to the culture medium of MDA-MB-231 breast cancer cells inhibits the 
expression of the protein i21VEGFR-1 [24]. The effect of retinoic acid on the expression of the 
intracellular truncated isoform of VEGFR-1 could be mediated by the Notch or/and miR-200 
pathways. Retinoic acid does not change the expression of Notch-1 in MDA-MB-231 cells [24]. 
However, the expression of Notch-3 decreases markedly [24]. This observation is in agreement with a 
previous finding of downregulation of Notch-3 expression by retinoic acid in MCF7 breast cancer  
cells [80]. Moreover, retinoic acid increases the expression of the miR-200 family of micro RNAs in 
MDA-MB-231 breast cancer cells [24]. MDA-MB-231 breast cancer cells treated with retinoic acid 
showed an increase in the expression of miR-200a, miR-200b and miR-200c [24]. An inverse relationship 
between miR200 expression and Notch activity has been previously reported in MDA-MB-231 breast 
cancer cells [81]. Links between γ-secretase inhibitors, retinoic acid, Notch pathway, miR-200 and 
i21VEGFR-1 are shown in (Figure 6). Both γ-secretase inhibitors and retinoic acid have been proposed 
as potential therapies for invasive breast cancer.  
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Figure 6. Expression of i21VEGFR-1 is positively regulated by the Notch pathway and 
negatively regulated by the micro RNA family miR-200. Addition of retinoic acid to the 
culture medium of MDA-MB-231 breast cancer cells inhibits the expression of the protein 
i21VEGFR-1. The effect of retinoic acid on the expression of the intracellular truncated 
isoform of VEGFR-1 is mediated by downregulation of Notch-3 expression. Moreover, 
retinoic acid increases the expression of the miR-200 family of micro RNAs in MDA-MB-231 
breast cancer cells. The expression of the truncated intracellular protein i21VEGFR-1 
decreases when the Notch signaling pathway is interfered with γ-secretase inhibitors. 
 
8. KIT, Truncated Intracellular KIT, and Cancer 
As previously indicated, transfection of KITB to NIHT3 fibroblasts is tumorigenic in mice [30]. 
Mutations of KIT are associated with gastrointestinal stromal tumors, myeloid leukemias and testicular 
seminomas [82,83]. These mutations induce ligand-independent dimerization and autophosphorylation 
of KIT and constitutive activation of downstream signaling pathways. 
Expression of the intracellular truncated isoform of KIT has been observed in 30% of the 
gastrointestinal and hematopoietic tumor cell lines studied [84]. Western blot analysis of 23 primary 
prostate cancers indicated that tr-KIT was expressed in ~28% of the tumors at less advanced stages and 
in 66% of those at more advanced stages, whereas it was not expressed in benign prostatic 
hypertrophies [36]. Prostate cancer cell lines and tumors expressing the tr-KIT have higher levels of 
phosphorylated/activated Src than tr-KIT-negative cells and tumors. Transfection of tr-KIT into 
prostate cancer cells caused a dramatic increase in Src activity. Sam68, an RNA-binding protein 
phosphorylated by Src, is phosphorylated only in prostate tumors expressing the tr-KIT. These 
observations by Paronetto et al. [37] showed for the first time the existence of a truncated c-KIT 
protein in primary tumors and showed a correlation between tr-KIT expression and activation of the 
Src pathway in the advanced stages of the disease.  
9. Structural and Functional Similarities between Truncated Intracellular Isoforms of VEGFR-1 
and KIT 
Since the intracellular C-terminal truncated isoforms of KIT and i21VEGFR-1 are similar in 
structure, and both activate Src [23,37], it is possible that these proteins share similar functions. The 
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truncated intracellular isoform of KIT is expressed in post-meiotic stages of spermatogenesis [34]. 
When microinjected into mouse eggs, truncated intracellular KIT causes parthenogenetic activation 
through activation of Src family kinases, suggesting that it might play a role in fertilization [37]. Two 
truncated intracellular isoforms of VEGFR-1, i19VEGFR-1 and i28VEGFR-1, are expressed in human 
testis (GenBank JF509744 and JF509745). We do not know if i19VEGFR-1 and i28VEGFR-1 have a 
similar function to tr-KIT in parthenogenetic activation of eggs. In addition to this function, there is the 
possibility that the truncated intracellular isoforms of VEGFR-1 and KIT, present in spermatozoa, may 
activate Src during the process of capacitation, a pre-requisite that allows spermatozoa to gain the 
ability to fertilize an oocyte. Src activation is critical to promote the tyrosine phosphorylation events 
associated with human sperm capacitation [85].  
Another function of i21VEGFR-1 and tr-KIT is their capacity to induce cancer cell invasiveness [23]. 
While the full length transmembrane receptor VEGFR-1 can induce migration and invasion through 
activation of Src, the truncated C-terminal intracellular isoform i21VEGFR-1 is able to activate Src in 
the absence of tyrosine kinase receptor ligands or the full length transmembrane receptor [23]. Cancer 
therapies based on the interference of ligands or receptors should consider the possibility of 
intracellular activation of Src by truncated isoforms. Due to the critical role of transient Src activation 
in the signaling circuit responsible for transformation and tumorigenesis, it is possible that the 
truncated isoform i21VEGFR-1 could be integrated into this circuit. 
Another interesting question is the relationship between the truncated isoforms and cell stemness. 
The truncated intracellular KIT is expressed in hematopoietic stem cells and multipotent progenitors, 
but not in more differentiated cells. The c-KIT receptor and its ligand stem cell factor play an 
important role for the maintenance and differentiation of hematopoietic stem cells and multipotent 
progenitors [1,2]. Besides c-KIT, murine hematopoietic stem cells and multipotent progenitors also 
express the truncated intracellular form of the c-KIT receptor [35]. In contrast to c-KIT, whose 
expression is more widespread during murine hematopoiesis, tr-KIT expression is restricted to cell 
populations enriched for hematopoietic stem cells and multipotent progenitors. The truncated transcript 
and protein were downregulated when differentiation of primitive hematopoietic cells was induced 
with cytokines and retinoic acid. Interestingly, similar to a previous observation in mouse 
spermatogenesis [37], in hematopoietic cells, tr-KIT is phosphorylated at the C-terminal tyrosine 
Y161, through an as yet unidentified process. Expression of the truncated, ligand independent, isoform 
could play a specific role in hematopoietic stem and pluripotent progenitors. 
10. Conclusions 
There is still much work to be done to understand the biological and pathological functions of the 
truncated intracellular isoforms. However, the implication of i21VEGFR-1 in Src activation and the 
relevance of Src activation driving transformation, invasion, tumorigenesis and inflammation, could 
make the expression of i21VEGFR-1 an interesting therapeutic target for cancer and inflammation. 
Reversible proteasome inhibitors have emerged as a promising approach to the treatment of cancer and 
inflammatory diseases. We have shown that both the expression of VEGFR-1 and i21VEGFR-1 is 
downregulated by the reversible proteasome inhibitor MG262 [86]. More recently [24], we have 
studied the effect of a γ-secretase inhibitor, retinoic acid and the micro RNA miR-200c in the 
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expression of i21VEGFR-1. As we have previously indicated, all these mechanisms are able to inhibit 
the expression of the VEGFR-1 intracellular truncated isoform. Particularly effective is the 
combination of the γ-secretase inhibitor and retinoic acid that almost completely abolishes the 
expression of the isoform. Both γ-secretase inhibitors and retinoic acid are being studied as potential 
therapies for breast cancer [80,87]. 
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